SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 18, 2009--
Exelixis, Inc. (Nasdaq:EXEL) announced today that George Scangos, PhD,
the company’s president and chief executive officer, will present at the
JMP Securities Eighth Annual Research Conference at 1:30 p.m. EDT /
10:30 a.m. PDT on Wednesday, May 20, 2009. Dr. Scangos will discuss the
company’s development pipeline and corporate strategy.
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors on the Exelixis website at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis’ broad product pipeline includes
investigational compounds in phase 3, phase 2, and phase 1 clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Boehringer Ingelheim,
Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please
visit the company’s web site at www.exelixis.com.
Source: Exelixis, Inc.
Exelixis, Inc.
Investor Contact:
Charles
Butler, 650-837-7277
Executive Director,
Corporate
Communications
cbutler@exelixis.com
Media
Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior
Manager,
Corporate Communications
sharrison@exelixis.com